Frontline and Sequential Strategies in HER2-Positive Breast Cancer: Integrating Emerging Evidence into Practice

Segment 1 establishes the current treatment landscape for HER2-positive metastatic breast cancer (mBC) and highlights key unmet clinical needs.

Experts discuss evolving strategies and unmet needs in HER2-positive breast cancer treatment, focusing on emerging therapies and clinical trial insights.

Experts discuss the evolving strategies in HER2-positive breast cancer treatment, focusing on maintenance therapies and patient-specific approaches.

New trials reveal T-DXd's effectiveness in high-risk HER2-positive breast cancer, showing significant improvements in treatment response rates.

Experts discuss the low incidence of ILD in T-DXd trials and the importance of vigilant screening in neoadjuvant settings for better patient outcomes.